Voyager Therapeutics (VYGR) Equity Average (2015 - 2026)

Voyager Therapeutics' Equity Average history runs 12 years deep, the most recent figure standing at $184.9 million for Q1 2026.

• In Q1 2026, Equity Average fell 35.41% year-over-year to $184.9 million; the TTM figure through Mar 2026 stood at $184.9 million (down 35.41% YoY), while the FY2025 annual figure was $247.9 million, down 7.51% from the prior year.
• Equity Average came in at $184.9 million for Q1 2026 at Voyager Therapeutics, down from $208.0 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $338.2 million in Q2 2024 to a low of $68.0 million in Q2 2022.
• A 5-year average of $204.5 million and a median of $208.0 million in 2025 frame the typical range for Equity Average.
• Across the five-year window, Equity Average tumbled 44.89% in 2022 and surged 205.91% in 2023, its largest moves.
• Voyager Therapeutics' Equity Average stood at $69.4 million in 2022, then soared by 197.13% to $206.3 million in 2023, then jumped by 52.73% to $315.0 million in 2024, then slumped by 33.99% to $208.0 million in 2025, then declined by 11.1% to $184.9 million in 2026.
• According to Business Quant data, Equity Average over the past three periods registered $184.9 million, $208.0 million, and $231.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison